An estimated seven to ten million people worldwide are living with Parkinson’s disease (PD), which is an incurable and progressive disease of the nervous system affecting movement and cognitive function. More than half of PD patients develop progressive disease showing signs of dementia similar to Alzheimer’s disease.
A research team at University of Copenhagen, Denmark, has discovered that non-inheritable PD may be caused by functional changes in the immune regulating gene Interferon-beta (IFNβ). Treatment with IFNβ-gene therapy successfully prevented neuronal death and disease effects in an experimental model of PD.
Protein Regulates Cell Waste Management
The human brain consists of approximately 100 billion neurons, which coordinate activities in all parts of the body. At Biotech Research and Innovation Centre (BRIC), University of Copenhagen, the group of Professor Shohreh Issazadeh-Navikas has discovered that the immune gene IFNβ plays a vital role in keeping neurons healthy.
“We found that IFNβ is essential for neurons ability to recycle waste proteins. Without this, the waste proteins accumulate in disease-associated structures called Lewy bodies and with time the neurons die,” explains Patrick Ejlerskov, first author.
The research team found that mice missing IFNβ developed Lewy bodies in parts of the brain, which control body movement and restoration of memory, and as a result they developed disease and clinical signs similar to patients with PD and dementia with Lewy bodies (DLB).
While hereditary gene mutations have long been known to play a role in familial PD, the study from BRIC offers one of the first models for so-called non-familial PD, which comprises the majority (90-95%) of patients suffering from PD. According to professor Shohreh Issazadeh-Navikas the new knowledge opens new therapeutic possibilities:
“This is one of the first genes found to cause pathology and clinical features of non-familial PD and DLB, through accumulation of disease-causing proteins. It is independent of gene mutations known from familial PD and when we introduced IFNβ-gene therapy, we could prevent neuronal death and disease development. Our hope is that this knowledge will enable development of more effective treatment of PD,” says professor Shohreh Issazadeh-Navikas.
Current treatments are effective at improving the early motor symptoms of the disease, however, as the disease progress, the treatment effect is lost. The next step for the research team will be to gain a better understanding of the molecular mechanisms by which IFN? protects neurons and thereby prevents movement disorders and dementia.
Patrick Ejlerskov, Jeanette Göransdotter Hultberg, JunYang Wang, Robert Carlsson, Malene Ambjørn, Martin Kuss, Yawei Liu, Giovanna Porcu, Kateryna Kolkova, Carsten Friis Rundsten, Karsten Ruscher, Bente Pakkenberg, Tobias Goldmann, Desiree Loreth, Marco Prinz, David C. Rubinsztein, Shohreh Issazadeh-Navikas Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia Cell, 2015; 163 (2): 324 DOI: 10.1016/j.cell.2015.08.069
Top Illustration: Thomas Ried, NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health